1.	Stereotactic Body Radiotherapy for Spine Tumors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-044, NCT01347307
2.	Stereotactic Body Radiotherapy for Liver Tumors Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-045, NCT01347333
3.	Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000646803, RTOG-0631, NCT00922974
4.	Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: OV21, CAN-NCIC-OV21, UCL08/0379, GEICO-0902, SWOG OV.21, CDR0000655241, NCT00993655
5.	Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CZOL446E2352, NCT00320710
6.	Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor Phase: Phase III Type: Treatment Status: Active Age: Under 30 Sponsor: NCI, Other Protocol IDs: CDR0000496508, COG-AREN0533, AREN0533, NCT00379340
7.	Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000499633, NCCTG-N0574, ACOSOG-N0574, N0574, NCT00377156
8.	Resection Bed Post-Surgical Stereotactic Radiosurgery (SRS) Phase: Phase III Type: Treatment Status: Active Age: 3 and over Sponsor: Other Protocol IDs: 2009-0381, NCT00950001
9.	Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000662707, CALGB-30801, NCT01041781
10.	Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-154, NCT01223248
11.	Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20090482, NCT01345019
12.	Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgery Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000701474, NCCTG-N107C, N107C, NCT01372774
13.	Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TS-102, NCT01483027
14.	Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-306, NCT01522443
15.	A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0884, NCT01592968
16.	Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-307, 2012-001834-33, NCT01605227
17.	Melanoma Gamma Knife Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0875, NCT01644591
18.	FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: STX0112, NCT01721954
19.	Phase I/II Study of Intraoperative Radiotherapy Using the INTRABEAM® System in Patients Undergoing Resection of a Solitary Brain Metastasis. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CCF-IRB-7003, CCF-510K, CCF-K992577, CCF-CTSRC-1065, NCT00107367
20.	Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: 424Sm32, NCT00121095
21.	Hepatic Artery Infusion With Oxaliplatin Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HRRC#341-05, NCT00244348
22.	Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 06-0906, NCT00463060
23.	Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
24.	Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 105-08-201, NCT00826085
25.	Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 040803, P30CA072720, CDR0000648116, 0220090058, CRAD001C2448;, CINJ-040803, NOVARTIS-CINJ-040803, NCT00934895